EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection

Lun Zhang, Jiamin Zheng, Rashid A Bux, Jean-François Haince iD, Claudia Torres-Calzada, Rupasri Mandal, Andrew Maksymiuk, Guoyu Huang iD, Paramjit S Tappia iD, Philippe Joubert iD, Christian D Rolfo, David S Wishart iD

International Journal of Molecular Sciences · 09.05.2025 · 26 (10) · 4519

DOI: 10.3390/ijms26104519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2025. Verfasst von Lun Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Metabolomics Innovation Centre, University of Alberta, Edmonton, AB T6G 2E8, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Early Detection of Cancer, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medteq (Impact Program), Province of Quebec, Canada, Medteq (Impact Program), Fonds de recherche Québec–Santé Québec (FRQS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early detection of lung cancer significantly improves survival, yet current screening methods have limitations. This study aimed to identify a robust panel of plasma metabolites for early-stage non-small cell lung cancer (NSCLC) diagnosis using a large, clinically diverse patient cohort. A total of 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls (including healthy individuals and patients with non-cancerous lung diseases) were analyzed using targeted, quantitative mass spectrometry-based metabolomics and used as the discovery cohort. An independent set of 216 plasma samples served as the validation cohort. Logistic regression (LR) models developed from the discovery set using ten metabolites achieved area under the receiver-operating characteristic curve (AUROC) values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, stage I–II, and stage I NSCLC patients from controls, respectively. Incorporating smoking history further improved model performance. The validation cohort confirmed the model’s robustness, demonstrating high sensitivity and specificity for early-stage detection. These results support the potential of metabolomic biomarkers as a minimally invasive, accurate tool for early NSCLC diagnosis. This approach may complement current screening methods, enabling earlier intervention and improved patient outcomes. Further studies are warranted to validate these findings in more diverse populations and real-world clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsBiomarkers, TumorEarly Detection of CancerCarcinoma, Non-Small-Cell LungMetabolomicsHumansFemaleMaleMiddle AgedAgedROC CurveCase-Control StudiesNeoplasm StagingMetabolomeAdult

Stichwörter der Autor:innen

early detectionmetabolite markersnon-small cell lung cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • The Metabolomics Innovation Centre, University of Alberta, Edmonton, AB T6G 2E8, Canada.
  • BioMark Diagnostics Inc., Richmond, BC V6X 2W2, Canada.
  • Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E8, Canada.
  • Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada.
  • Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.
  • Asper Clinical Research Institute, St. Boniface Hospital, Winnipeg, MB R2H 2A6, Canada.

ORCID-Profile: Jean-François Haince, Guoyu Huang, Paramjit S Tappia, Philippe Joubert, David S Wishart

Förderung

  • Medteq (Impact Program), Province of Quebec, Canada
  • Medteq (Impact Program)
  • Fonds de recherche Québec–Santé Québec (FRQS)

Zitieren

APA

Zhang, L., Zheng, J., Bux, R. A., Haince, J. F., Torres-Calzada, C., Mandal, R., Maksymiuk, A., Huang, G., Tappia, P. S., Joubert, P., Rolfo, C. D., & Wishart, D. S. (2025). Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection. International Journal of Molecular Sciences, 26(10), 4519. https://doi.org/10.3390/ijms26104519

Vancouver

Zhang L, Zheng J, Bux RA, Haince JF, Torres-Calzada C, Mandal R, et al. Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection. International Journal of Molecular Sciences. 2025;26(10):4519. doi:10.3390/ijms26104519

BibTeX
@article{Zhang2025,
  author = {Zhang, Lun and Zheng, Jiamin and Bux, Rashid A and Haince, Jean-François and Torres-Calzada, Claudia and Mandal, Rupasri and Maksymiuk, Andrew and Huang, Guoyu and Tappia, Paramjit S and Joubert, Philippe and Rolfo, Christian D and Wishart, David S},
  title = {Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {10},
  pages = {4519},
  doi = {10.3390/ijms26104519}
}
Kostenlos starten →